Loading…

Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach

The manipulation of chaperone levels has been shown to inhibit aggregation and/or rescue cell death in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and cell culture models of Huntington's disease (HD) and other polyglutamine (polyQ) disorders. We show here that a pr...

Full description

Saved in:
Bibliographic Details
Published in:Human molecular genetics 2004-07, Vol.13 (13), p.1389-1405
Main Authors: Hay, David G., Sathasivam, Kirupa, Tobaben, Sönke, Stahl, Bernd, Marber, Michael, Mestril, Ruben, Mahal, Amarbirpal, Smith, Donna L., Woodman, Ben, Bates, Gillian P.
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c409t-98539364f3c67fcdfa02d87605fed15bf80da1463cc45eae7165f814e5d228123
cites
container_end_page 1405
container_issue 13
container_start_page 1389
container_title Human molecular genetics
container_volume 13
creator Hay, David G.
Sathasivam, Kirupa
Tobaben, Sönke
Stahl, Bernd
Marber, Michael
Mestril, Ruben
Mahal, Amarbirpal
Smith, Donna L.
Woodman, Ben
Bates, Gillian P.
description The manipulation of chaperone levels has been shown to inhibit aggregation and/or rescue cell death in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and cell culture models of Huntington's disease (HD) and other polyglutamine (polyQ) disorders. We show here that a progressive decrease in Hdj1, Hdj2, Hsp70, αSGT and βSGT brain levels likely contributes to disease pathogenesis in the R6/2 mouse model of HD. Despite a predominantly extranuclear location, Hdj1, Hdj2, Hsc70, αSGT and βSGT were found to co-localize with nuclear but not with extranuclear aggregates. Quantification of Hdj1 and αSGT mRNA levels showed that these do not change and therefore the decrease in protein levels may be a consequence of their sequestration to aggregates, or an increase in protein turnover, possibly as a consequence of their relocation to the nucleus. We have used genetic and pharmacological approaches to assess the therapeutic potential of chaperone manipulation. Ubiquitous overexpression of Hsp70 in the R6/2 mouse (as a result of crossing to Hsp70 transgenics) delays aggregate formation by 1 week, has no effect on the detergent solubility of aggregates and does not alter the course of the neurological phenotype. We used an organotypic slice culture assay to show that pharmacological induction of the heat shock response might be a more useful approach. Radicicol and geldanamycin could both maintain chaperone induction for at least 3 weeks and alter the detergent soluble properties of polyQ aggregates over this time course.
doi_str_mv 10.1093/hmg/ddh144
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72012468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72012468</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-98539364f3c67fcdfa02d87605fed15bf80da1463cc45eae7165f814e5d228123</originalsourceid><addsrcrecordid>eNqF0d2K1DAUB_Agijuu3vgAEgQVhLr5TnOpizrigF4oiDchm5zMdG3T2aRd9D18YFNn_MAbIVDI-XFOTv8I3afkGSWGn-2G7VkIOyrEDbSiQpGGkZbfRCtilGiUIeoE3SnlkhCqBNe30QmVlEqt1Ap9f5_HbYZSumvAAXwGVwB3Cfud20MeE-B9HieoNz1cQ1-WmsPDOFc2jAF6PEa8ntPUpe00picFh678bOJSqDjMfurGtKgyLYN-9SvY1YOnHeQ6aZ46j92-1pzf3UW3ousL3Dt-T9HHVy8_nK-bzbvXb86fbxoviJka00puuBKRe6WjD9ERFlqtiIwQqLyILQmu_g_uvZDgQFMlY0sFyMBYSxk_RY8PfevYqxnKZIeueOh7l6AuaDUjlAnV_hdSY4xiTFb48B94Oc451SUso5QZxpWu6OkB-TyWkiHafe4Gl79ZSuySqK2J2kOiFT84dpwvBgh_6DHCCh4dgSve9TG75LvylzOCab3s0BxcVyb4-rvu8hdb36SlXX_6bBkT4sVGvbWC_wD-OrqX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>211292367</pqid></control><display><type>article</type><title>Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach</title><source>Oxford Journals Online</source><creator>Hay, David G. ; Sathasivam, Kirupa ; Tobaben, Sönke ; Stahl, Bernd ; Marber, Michael ; Mestril, Ruben ; Mahal, Amarbirpal ; Smith, Donna L. ; Woodman, Ben ; Bates, Gillian P.</creator><creatorcontrib>Hay, David G. ; Sathasivam, Kirupa ; Tobaben, Sönke ; Stahl, Bernd ; Marber, Michael ; Mestril, Ruben ; Mahal, Amarbirpal ; Smith, Donna L. ; Woodman, Ben ; Bates, Gillian P.</creatorcontrib><description>The manipulation of chaperone levels has been shown to inhibit aggregation and/or rescue cell death in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and cell culture models of Huntington's disease (HD) and other polyglutamine (polyQ) disorders. We show here that a progressive decrease in Hdj1, Hdj2, Hsp70, αSGT and βSGT brain levels likely contributes to disease pathogenesis in the R6/2 mouse model of HD. Despite a predominantly extranuclear location, Hdj1, Hdj2, Hsc70, αSGT and βSGT were found to co-localize with nuclear but not with extranuclear aggregates. Quantification of Hdj1 and αSGT mRNA levels showed that these do not change and therefore the decrease in protein levels may be a consequence of their sequestration to aggregates, or an increase in protein turnover, possibly as a consequence of their relocation to the nucleus. We have used genetic and pharmacological approaches to assess the therapeutic potential of chaperone manipulation. Ubiquitous overexpression of Hsp70 in the R6/2 mouse (as a result of crossing to Hsp70 transgenics) delays aggregate formation by 1 week, has no effect on the detergent solubility of aggregates and does not alter the course of the neurological phenotype. We used an organotypic slice culture assay to show that pharmacological induction of the heat shock response might be a more useful approach. Radicicol and geldanamycin could both maintain chaperone induction for at least 3 weeks and alter the detergent soluble properties of polyQ aggregates over this time course.</description><identifier>ISSN: 0964-6906</identifier><identifier>ISSN: 1460-2083</identifier><identifier>EISSN: 1460-2083</identifier><identifier>DOI: 10.1093/hmg/ddh144</identifier><identifier>PMID: 15115766</identifier><identifier>CODEN: HNGEE5</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Animals ; Benzoquinones ; Biological and medical sciences ; Brain - metabolism ; Brain - pathology ; Caenorhabditis elegans ; Cell Nucleus - metabolism ; Cells, Cultured ; Crosses, Genetic ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Disease Models, Animal ; Drosophila melanogaster ; Enzyme Inhibitors - pharmacology ; Fundamental and applied biological sciences. Psychology ; Gene Expression Regulation - drug effects ; Genetics of eukaryotes. Biological and molecular evolution ; Huntington Disease - metabolism ; Huntington Disease - pathology ; Lactams, Macrocyclic ; Lactones - pharmacology ; Macrolides ; Medical sciences ; Mice ; Molecular and cellular biology ; Molecular Chaperones - genetics ; Molecular Chaperones - metabolism ; Neurology ; Peptides - metabolism ; Quinones - pharmacology ; RNA, Messenger - biosynthesis ; Saccharomyces cerevisiae</subject><ispartof>Human molecular genetics, 2004-07, Vol.13 (13), p.1389-1405</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Oxford University Press</rights><rights>Copyright Oxford University Press(England) Jul 1, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-98539364f3c67fcdfa02d87605fed15bf80da1463cc45eae7165f814e5d228123</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15942778$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15115766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hay, David G.</creatorcontrib><creatorcontrib>Sathasivam, Kirupa</creatorcontrib><creatorcontrib>Tobaben, Sönke</creatorcontrib><creatorcontrib>Stahl, Bernd</creatorcontrib><creatorcontrib>Marber, Michael</creatorcontrib><creatorcontrib>Mestril, Ruben</creatorcontrib><creatorcontrib>Mahal, Amarbirpal</creatorcontrib><creatorcontrib>Smith, Donna L.</creatorcontrib><creatorcontrib>Woodman, Ben</creatorcontrib><creatorcontrib>Bates, Gillian P.</creatorcontrib><title>Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach</title><title>Human molecular genetics</title><addtitle>Hum. Mol. Genet</addtitle><description>The manipulation of chaperone levels has been shown to inhibit aggregation and/or rescue cell death in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and cell culture models of Huntington's disease (HD) and other polyglutamine (polyQ) disorders. We show here that a progressive decrease in Hdj1, Hdj2, Hsp70, αSGT and βSGT brain levels likely contributes to disease pathogenesis in the R6/2 mouse model of HD. Despite a predominantly extranuclear location, Hdj1, Hdj2, Hsc70, αSGT and βSGT were found to co-localize with nuclear but not with extranuclear aggregates. Quantification of Hdj1 and αSGT mRNA levels showed that these do not change and therefore the decrease in protein levels may be a consequence of their sequestration to aggregates, or an increase in protein turnover, possibly as a consequence of their relocation to the nucleus. We have used genetic and pharmacological approaches to assess the therapeutic potential of chaperone manipulation. Ubiquitous overexpression of Hsp70 in the R6/2 mouse (as a result of crossing to Hsp70 transgenics) delays aggregate formation by 1 week, has no effect on the detergent solubility of aggregates and does not alter the course of the neurological phenotype. We used an organotypic slice culture assay to show that pharmacological induction of the heat shock response might be a more useful approach. Radicicol and geldanamycin could both maintain chaperone induction for at least 3 weeks and alter the detergent soluble properties of polyQ aggregates over this time course.</description><subject>Animals</subject><subject>Benzoquinones</subject><subject>Biological and medical sciences</subject><subject>Brain - metabolism</subject><subject>Brain - pathology</subject><subject>Caenorhabditis elegans</subject><subject>Cell Nucleus - metabolism</subject><subject>Cells, Cultured</subject><subject>Crosses, Genetic</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Disease Models, Animal</subject><subject>Drosophila melanogaster</subject><subject>Enzyme Inhibitors - pharmacology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Genetics of eukaryotes. Biological and molecular evolution</subject><subject>Huntington Disease - metabolism</subject><subject>Huntington Disease - pathology</subject><subject>Lactams, Macrocyclic</subject><subject>Lactones - pharmacology</subject><subject>Macrolides</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Molecular and cellular biology</subject><subject>Molecular Chaperones - genetics</subject><subject>Molecular Chaperones - metabolism</subject><subject>Neurology</subject><subject>Peptides - metabolism</subject><subject>Quinones - pharmacology</subject><subject>RNA, Messenger - biosynthesis</subject><subject>Saccharomyces cerevisiae</subject><issn>0964-6906</issn><issn>1460-2083</issn><issn>1460-2083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqF0d2K1DAUB_Agijuu3vgAEgQVhLr5TnOpizrigF4oiDchm5zMdG3T2aRd9D18YFNn_MAbIVDI-XFOTv8I3afkGSWGn-2G7VkIOyrEDbSiQpGGkZbfRCtilGiUIeoE3SnlkhCqBNe30QmVlEqt1Ap9f5_HbYZSumvAAXwGVwB3Cfud20MeE-B9HieoNz1cQ1-WmsPDOFc2jAF6PEa8ntPUpe00picFh678bOJSqDjMfurGtKgyLYN-9SvY1YOnHeQ6aZ46j92-1pzf3UW3ousL3Dt-T9HHVy8_nK-bzbvXb86fbxoviJka00puuBKRe6WjD9ERFlqtiIwQqLyILQmu_g_uvZDgQFMlY0sFyMBYSxk_RY8PfevYqxnKZIeueOh7l6AuaDUjlAnV_hdSY4xiTFb48B94Oc451SUso5QZxpWu6OkB-TyWkiHafe4Gl79ZSuySqK2J2kOiFT84dpwvBgh_6DHCCh4dgSve9TG75LvylzOCab3s0BxcVyb4-rvu8hdb36SlXX_6bBkT4sVGvbWC_wD-OrqX</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Hay, David G.</creator><creator>Sathasivam, Kirupa</creator><creator>Tobaben, Sönke</creator><creator>Stahl, Bernd</creator><creator>Marber, Michael</creator><creator>Mestril, Ruben</creator><creator>Mahal, Amarbirpal</creator><creator>Smith, Donna L.</creator><creator>Woodman, Ben</creator><creator>Bates, Gillian P.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7SS</scope><scope>M7N</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach</title><author>Hay, David G. ; Sathasivam, Kirupa ; Tobaben, Sönke ; Stahl, Bernd ; Marber, Michael ; Mestril, Ruben ; Mahal, Amarbirpal ; Smith, Donna L. ; Woodman, Ben ; Bates, Gillian P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-98539364f3c67fcdfa02d87605fed15bf80da1463cc45eae7165f814e5d228123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Benzoquinones</topic><topic>Biological and medical sciences</topic><topic>Brain - metabolism</topic><topic>Brain - pathology</topic><topic>Caenorhabditis elegans</topic><topic>Cell Nucleus - metabolism</topic><topic>Cells, Cultured</topic><topic>Crosses, Genetic</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Disease Models, Animal</topic><topic>Drosophila melanogaster</topic><topic>Enzyme Inhibitors - pharmacology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Genetics of eukaryotes. Biological and molecular evolution</topic><topic>Huntington Disease - metabolism</topic><topic>Huntington Disease - pathology</topic><topic>Lactams, Macrocyclic</topic><topic>Lactones - pharmacology</topic><topic>Macrolides</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Molecular and cellular biology</topic><topic>Molecular Chaperones - genetics</topic><topic>Molecular Chaperones - metabolism</topic><topic>Neurology</topic><topic>Peptides - metabolism</topic><topic>Quinones - pharmacology</topic><topic>RNA, Messenger - biosynthesis</topic><topic>Saccharomyces cerevisiae</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hay, David G.</creatorcontrib><creatorcontrib>Sathasivam, Kirupa</creatorcontrib><creatorcontrib>Tobaben, Sönke</creatorcontrib><creatorcontrib>Stahl, Bernd</creatorcontrib><creatorcontrib>Marber, Michael</creatorcontrib><creatorcontrib>Mestril, Ruben</creatorcontrib><creatorcontrib>Mahal, Amarbirpal</creatorcontrib><creatorcontrib>Smith, Donna L.</creatorcontrib><creatorcontrib>Woodman, Ben</creatorcontrib><creatorcontrib>Bates, Gillian P.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Human molecular genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hay, David G.</au><au>Sathasivam, Kirupa</au><au>Tobaben, Sönke</au><au>Stahl, Bernd</au><au>Marber, Michael</au><au>Mestril, Ruben</au><au>Mahal, Amarbirpal</au><au>Smith, Donna L.</au><au>Woodman, Ben</au><au>Bates, Gillian P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach</atitle><jtitle>Human molecular genetics</jtitle><addtitle>Hum. Mol. Genet</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>13</volume><issue>13</issue><spage>1389</spage><epage>1405</epage><pages>1389-1405</pages><issn>0964-6906</issn><issn>1460-2083</issn><eissn>1460-2083</eissn><coden>HNGEE5</coden><abstract>The manipulation of chaperone levels has been shown to inhibit aggregation and/or rescue cell death in Saccharomyces cerevisiae, Caenorhabditis elegans, Drosophila melanogaster and cell culture models of Huntington's disease (HD) and other polyglutamine (polyQ) disorders. We show here that a progressive decrease in Hdj1, Hdj2, Hsp70, αSGT and βSGT brain levels likely contributes to disease pathogenesis in the R6/2 mouse model of HD. Despite a predominantly extranuclear location, Hdj1, Hdj2, Hsc70, αSGT and βSGT were found to co-localize with nuclear but not with extranuclear aggregates. Quantification of Hdj1 and αSGT mRNA levels showed that these do not change and therefore the decrease in protein levels may be a consequence of their sequestration to aggregates, or an increase in protein turnover, possibly as a consequence of their relocation to the nucleus. We have used genetic and pharmacological approaches to assess the therapeutic potential of chaperone manipulation. Ubiquitous overexpression of Hsp70 in the R6/2 mouse (as a result of crossing to Hsp70 transgenics) delays aggregate formation by 1 week, has no effect on the detergent solubility of aggregates and does not alter the course of the neurological phenotype. We used an organotypic slice culture assay to show that pharmacological induction of the heat shock response might be a more useful approach. Radicicol and geldanamycin could both maintain chaperone induction for at least 3 weeks and alter the detergent soluble properties of polyQ aggregates over this time course.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>15115766</pmid><doi>10.1093/hmg/ddh144</doi><tpages>17</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0964-6906
ispartof Human molecular genetics, 2004-07, Vol.13 (13), p.1389-1405
issn 0964-6906
1460-2083
1460-2083
language eng
recordid cdi_proquest_miscellaneous_72012468
source Oxford Journals Online
subjects Animals
Benzoquinones
Biological and medical sciences
Brain - metabolism
Brain - pathology
Caenorhabditis elegans
Cell Nucleus - metabolism
Cells, Cultured
Crosses, Genetic
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Disease Models, Animal
Drosophila melanogaster
Enzyme Inhibitors - pharmacology
Fundamental and applied biological sciences. Psychology
Gene Expression Regulation - drug effects
Genetics of eukaryotes. Biological and molecular evolution
Huntington Disease - metabolism
Huntington Disease - pathology
Lactams, Macrocyclic
Lactones - pharmacology
Macrolides
Medical sciences
Mice
Molecular and cellular biology
Molecular Chaperones - genetics
Molecular Chaperones - metabolism
Neurology
Peptides - metabolism
Quinones - pharmacology
RNA, Messenger - biosynthesis
Saccharomyces cerevisiae
title Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T17%3A10%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Progressive%20decrease%20in%20chaperone%20protein%20levels%20in%20a%20mouse%20model%20of%20Huntington's%20disease%20and%20induction%20of%20stress%20proteins%20as%20a%20therapeutic%20approach&rft.jtitle=Human%20molecular%20genetics&rft.au=Hay,%20David%20G.&rft.date=2004-07-01&rft.volume=13&rft.issue=13&rft.spage=1389&rft.epage=1405&rft.pages=1389-1405&rft.issn=0964-6906&rft.eissn=1460-2083&rft.coden=HNGEE5&rft_id=info:doi/10.1093/hmg/ddh144&rft_dat=%3Cproquest_cross%3E72012468%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c409t-98539364f3c67fcdfa02d87605fed15bf80da1463cc45eae7165f814e5d228123%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=211292367&rft_id=info:pmid/15115766&rfr_iscdi=true